These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 37424174)

  • 1. Chinese Registry of Psoriatic Arthritis (CREPAR): I. Clinical characteristics of Chinese patients with psoriatic arthritis.
    Lu C; Yang F; Liu H; Dou L; Wang Y; Li H; Duan X; Wu L; Wang Y; Zhang X; Xu J; Su J; Xu D; Zhao J; Wu Q; Li M; Leng X; Zeng X;
    Int J Rheum Dis; 2023 Sep; 26(9):1737-1744. PubMed ID: 37424174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enthesitis in patients with psoriatic arthritis: A nationwide data from the Chinese Registry of Psoriatic Arthritis (CREPAR).
    Yang F; Lu C; Liu H; Dou L; Wang Y; Li H; Duan X; Wu L; Wang Y; Zhang X; Xu J; Su J; Xu D; Zhao J; Wu Q; Li M; Leng X; Zeng X
    Chin Med J (Engl); 2023 Apr; 136(8):951-958. PubMed ID: 37036901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Associations between family history of psoriatic disease and clinical characteristics on patients with psoriatic arthritis: a nationwide study from the Chinese Registry of Psoriatic Arthritis (CREPAR II).
    Liu H; Lu C; Yang F; Wang Y; Dou L; Li H; Su J; Zhang S; Li M; Tian X; Leng X; Zeng X;
    Clin Exp Rheumatol; 2023 Sep; 41(9):1901-1907. PubMed ID: 37199179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Composite Indices Tailored for Psoriatic Arthritis Treated with csDMARD and bDMARD: A Cross-sectional Analysis of a Longitudinal Cohort.
    Lubrano E; De Socio A; Perrotta FM
    J Rheumatol; 2017 Aug; 44(8):1159-1164. PubMed ID: 28572467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sex-specific differences in patients with psoriatic arthritis:a nationwide study from the Chinese Registry of Psoriatic Arthritis (CREPAR IV).
    He S; Yang F; Lu C; Wang Y; Duan X; Li H; Wu L; Wang Y; Su J; Li M; Leng X; Zeng X;
    Clin Rheumatol; 2024 Mar; 43(3):1063-1071. PubMed ID: 38200254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High disease relapse after bDMARD spacing in psoriatic arthritis compared to rheumatoid arthritis and axial spondyloarthritis patients: real-life data from BIOPURE registry.
    Fornaro M; Righetti G; Abbruzzese A; Lopalco G; Cacciapaglia F; Anelli MG; Venerito V; Iannone F
    Clin Rheumatol; 2021 Sep; 40(9):3659-3665. PubMed ID: 33864158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LOOP, a cross-sectional, observational study investigating the clinical specialty setting as a determinant of disease management in psoriatic arthritis: Subgroup analysis results from Japan.
    Okada M; Kurimoto S; Ganz F; Boehncke WH
    PLoS One; 2021; 16(1):e0245954. PubMed ID: 33503031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of disease-modifying anti-rheumatic drugs on bone structure and strength in psoriatic arthritis patients.
    Simon D; Kleyer A; Bayat S; Tascilar K; Kampylafka E; Meinderink T; Schuster L; Petrov R; Liphardt AM; Rech J; Schett G; Hueber AJ
    Arthritis Res Ther; 2019 Jul; 21(1):162. PubMed ID: 31269973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of new potential targets for remission and low disease activity in psoriatic arthritis in patients treated with golimumab.
    Coates LC; Rahman P; Psaradellis E; Rampakakis E; Osborne B; Lehman AJ; Nantel F
    Rheumatology (Oxford); 2019 Mar; 58(3):522-526. PubMed ID: 30517715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Very Low Disease Activity, DAPSA Remission, and Impact of Disease in a Spanish Population with Psoriatic Arthritis.
    Queiro R; Cañete JD; Montilla C; Abad MA; Montoro M; Gómez S; Cábez A;
    J Rheumatol; 2019 Jul; 46(7):710-715. PubMed ID: 30709957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Characteristics, Disease Activity, and Patient-Reported Outcomes in Psoriatic Arthritis Patients With Dactylitis or Enthesitis: Results From the Corrona Psoriatic Arthritis/Spondyloarthritis Registry.
    Mease PJ; Karki C; Palmer JB; Etzel CJ; Kavanaugh A; Ritchlin CT; Malley W; Herrera V; Tran M; Greenberg JD
    Arthritis Care Res (Hoboken); 2017 Nov; 69(11):1692-1699. PubMed ID: 28376239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug survival and effectiveness of ustekinumab in patients with psoriatic arthritis. Real-life data from the biologic Apulian registry (BIOPURE).
    Iannone F; Santo L; Bucci R; Semeraro A; Carlino G; Paoletti F; Quarta L; Leucci P; Zuccaro C; Marsico A; Scioscia C; D'Onofrio F; Mazzotta D; Muratore M; Cantatore FP; Lapadula G
    Clin Rheumatol; 2018 Mar; 37(3):667-675. PubMed ID: 29411182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psoriatic arthritis treatment regimens, therapy duration and reasons for cessation in the biologics era: a multi-centre Australian study.
    Tymms K; Kelly A; Bird P; Griffiths H; de Jager J; Littlejohn G; Louw S; Roberts L; Youssef P; Zochling J; Nichols D
    Int J Rheum Dis; 2018 Feb; 21(2):510-516. PubMed ID: 28730757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistence of tumor necrosis factor inhibitor or conventional synthetic disease-modifying antirheumatic drug monotherapy or combination therapy in psoriatic arthritis in a real-world setting.
    Mease PJ; Accortt NA; Rebello S; Etzel CJ; Harrison RW; Aras GA; Gharaibeh MMF; Greenberg JD; Collier DH
    Rheumatol Int; 2019 Sep; 39(9):1547-1558. PubMed ID: 31321485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA).
    Theander E; Husmark T; Alenius GM; Larsson PT; Teleman A; Geijer M; Lindqvist UR
    Ann Rheum Dis; 2014 Feb; 73(2):407-13. PubMed ID: 23355078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High rates of therapeutic changes in patients with psoriatic arthritis receiving treatment with disease-modifying antirheumatic drugs: A cross-sectional study.
    Behrens F; Rech J; Thaçi D; Zinke S; Rothnie KJ; Oefner Daamen C; Leipe J
    Mod Rheumatol; 2022 Jan; 32(1):87-95. PubMed ID: 32856975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minimal disease activity and impact of disease in psoriatic arthritis: a Spanish cross-sectional multicenter study.
    Queiro R; Cañete JD; Montilla C; Abad M; Montoro M; Gómez S; Cábez A;
    Arthritis Res Ther; 2017 Mar; 19(1):72. PubMed ID: 28356155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of minimal disease activity in Australian patients with Psoriatic Arthritis: Assessing the outcome of national funding criteria for biologic disease-modifying antirheumatic drug prescribing.
    Pontifex EK; Dissanayake K; Bursill D; Gill T
    Int J Rheum Dis; 2019 Feb; 22(2):262-268. PubMed ID: 30450819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Need for Improvement in Current Treatment of Psoriatic Arthritis: Study of an Outpatient Clinic Population.
    Michelsen B; Diamantopoulos AP; Høiberg HK; Soldal DM; Kavanaugh A; Haugeberg G
    J Rheumatol; 2017 Apr; 44(4):431-436. PubMed ID: 28148701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical characteristics, disease activity, functional status, and quality of life results of patients with psoriatic arthritis using biological and conventional synthetic disease-modifying antirheumatic drugs.
    Keskin Y; Nas K; Kiliç E; Sargin B; Acer Kasman S; Alkan H; Şahin N; Cengiz G; Cuzdan N; Albayrak Gezer İ; Keskin D; Mülkoğlu C; Resorlu H; Ataman Ş; Bal A; Duruoz MT; Küçükakkas O; Yurdakul OV; Alkan Melikoğlu M; Aydin Y; Ayhan FF; Bodur H; Çaliş M; Çapkin E; Devrimsel G; Gök K; Hizmetli S; Kamanli A; Ecesoy H; Kutluk Ö; Şen N; Şendur ÖF; Tekeoğlu İ; Tolu S; Toprak M; Tuncer T
    Arch Rheumatol; 2021 Mar; 36(1):1-9. PubMed ID: 34046563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.